Generic placeholder image

Current Women`s Health Reviews

Author(s): Alaa Ibrahim Ali *, Wassan Nori Mohammed Hassan and Sumaya Alrawi

DOI: 10.2174/1573404817666211208152049

DownloadDownload PDF Flyer Cite As
A Copeptin as a Predictor Marker for Insulin Resistance Among Women with Polycystic Ovary Syndrome

Article ID: e081221198670 Pages: 6

  • * (Excluding Mailing and Handling)

Abstract

Background: A polycystic ovarian syndrome (PCOS) is a common endocrine syndrome in which women have a wide range of clinical presentations; insulin resistance was linked to its pathogenesis.

Objective: We aimed to investigate the copeptin role as a predictive marker of insulin resistance among PCOS women.

Materials and Methods: In University Hospital, we included 280 women, with 140 of them being healthy controls. 140 out of 280 cases of PCOS subdivided into two groups depending on the insulin resistance; group 1 with homeostasis model assessment for the insulin resistance < 2.5. Group 2 with homeostasis model assessment for the insulin resistance >2.5. The evaluation of body mass index and blood pressure for all besides the blood sampling for estimation of a follicular stimulating hormone, luteinizing hormone, prolactin, estradiol, sex hormone-binding globulin, total testosterone, fasting insulin dehydroepiandrosterone sulfate, C-reactive protein, plasma glucose, free androgen index, and plasma copeptin using the Copeptin-Human EIA Kit besides the transvaginal ultrasound for ovarian assessment.

Results: When compared to other groups, PCOS women with positive insulin resistance >2.5 had a significantly higher plasma copeptin level. The ROC curve calculated a 1.94 pmol/L; plasma copeptin cutoff value for detecting the insulin resistance in PCOS with 88 % sensitivity value and 36 % specificity, AUC was 0.88.

Conclusion: The significant positive relationship between serum copeptin and insulin resistance with high sensitivity implies its usefulness as a marker of insulin resistance among PCOS patients with a high prediction of its complication.

Keywords: Polycystic ovarian syndrome, plasma copeptin, insulin resistance, metabolic syndrome, arginine vasopressin, Copeptin.

Graphical Abstract

[1]
Bani Mohammad M, Majdi Seghinsara A. Polycystic Ovary Syndrome (PCOS), diagnostic criteria, and AMH. Asian Pac J Cancer Prevent 2017; 18(1): 17-21. http://dx.doi.org/10.22034%2FAPJCP.2017.18.1.17 PMID: 28240001
[2]
Ünlütürk U, Sezgin E, Yildiz BO. Evolutionary determinants of polycystic ovary syndrome: Part 1. Fertil Steril 2016; 106(1): 33-41.
[http://dx.doi.org/10.1016/j.fertnstert.2016.05.010] [PMID: 27238626]
[3]
Ibáñez L, Oberfield SE, Witchel S, et al. An international consortium update: Pathophysiology, diagnosis, and treatment of polycystic ovarian syndrome in adolescence. Horm Res Paediatr 2017; 88(6): 371-95.
[http://dx.doi.org/10.1159/000479371] [PMID: 29156452]
[4]
Azziz R. PCOS in 2015: New insights into the genetics of polycystic ovary syndrome. Nat Rev Endocrinol 2016; 12(2): 74-5.
[http://dx.doi.org/10.1038/nrendo.2015.230] [PMID: 26729036]
[5]
Dumesic DA, Hoyos LR, Chazenbalk GD, Naik R, Padmanabhan V, Abbott DH. Mechanisms of intergenerational transmission of polycystic ovary syndrome. Reproduction 2020; 159(1): R1-R13.
[http://dx.doi.org/10.1530/REP-19-0197] [PMID: 31376813]
[6]
Roger H, Dorota AD. The potential implications of a PCOS diagnosis on a woman’s long-term health using data linkage. J Clin Endocrinol Metab 2015; 100: 911-9.
[http://dx.doi.org/10.1210/jc.2014-3886]
[7]
Nori W, Abdulghani M, Roomi AB, et al. To operate or to wait? Doppler indices as predictors for medical termination for first trimester missed abortion. Clin Exp Obstet Gynecol 2021; 48(1): 168-74.
[http://dx.doi.org/10.31083/j.ceog.2021.01.2215]
[8]
Polak K, Czyzyk A, Simoncini T, Meczekalski B. New markers of insulin resistance in polycystic ovary syndrome. J Endocrinol Invest 2017; 40(1): 1-8.
[http://dx.doi.org/10.1007/s40618-016-0523-8] [PMID: 27473078]
[9]
Govender N, Moodley J, Naicker T. Copeptin in preeclampsia development. Curr Womens Health Rev 2019; 15(3): 159-64.
[http://dx.doi.org/10.2174/1573404815666190110094636]
[10]
Enhörning S, Struck J, Wirfält E, Hedblad B, Morgenthaler NG, Melander O. Plasma copeptin, a unifying factor behind the metabolic syndrome. J Clin Endocrinol Metab 2011; 96(7): E1065-72.
[http://dx.doi.org/10.1210/jc.2010-2981] [PMID: 21490073]
[11]
Glueck CJ, Goldenberg N. Characteristics of obesity in polycystic ovary syndrome: Etiology, treatment, and genetics. Metabolism 2019; 92: 108-20.
[http://dx.doi.org/10.1016/j.metabol.2018.11.002] [PMID: 30445140]
[12]
Nishina K, Takagishi H, Takahashi H, Sakagami M, Inoue-Murayama M. Association of polymorphism of Arginine-Vasopressin Receptor 1A (AVPR1a) gene with trust and reciprocity. Front Hum Neurosci 2019; 13: 230.
[http://dx.doi.org/10.3389/fnhum.2019.00230] [PMID: 31354450]
[13]
Ojeda-Ojeda M, Murri M, Insenser M, Escobar-Morreale HF. Mediators of low-grade chronic inflammation in Polycystic Ovary Syndrome (PCOS). Curr Pharm Des 2013; 19(32): 5775-91.
[http://dx.doi.org/10.2174/1381612811319320012] [PMID: 23448487]
[14]
Hoeger KM, Dokras A, Piltonen T. Update on PCOS: Consequences, challenges, and guiding treatment. J Clin Endocrinol Metab 2021; 106(3): e1071-83.
[http://dx.doi.org/10.1210/clinem/dgaa839] [PMID: 33211867]
[15]
Kautzky-Willer A, Harreiter J, Pacini G. Sex and gender differences in risk, pathophysiology and complications of type 2 diabetes mellitus. Endocr Rev 2016; 37(3): 278-316.
[http://dx.doi.org/10.1210/er.2015-1137] [PMID: 27159875]
[16]
Ilias I, Goulas S, Zabuliene L. Polycystic ovary syndrome: Pathways and mechanisms for possible increased susceptibility to COVID-19. World J Clin Cases 2021; 9(12): 2711-20.
[http://dx.doi.org/10.12998/wjcc.v9.i12.2711] [PMID: 33969054]
[17]
August GP, Caprio S, Fennoy I, et al. Prevention and treatment of pediatric obesity: An endocrine society clinical practice guideline based on expert opinion. J Clin Endocrinol Metab 2008; 93(12): 4576-99.
[http://dx.doi.org/10.1210/jc.2007-2458] [PMID: 18782869]
[18]
Frøssing S, Nylander M, Kistorp C, Skouby SO, Faber J. Effect of liraglutide on atrial natriuretic peptide, adrenomedullin, and copeptin in PCOS. Endocr Connect 2018; 7(1): 115-23.
[http://dx.doi.org/10.1530/EC-17-0327] [PMID: 29295870]
[19]
Rudnicka E, Suchta K, Grymowicz M, et al. Chronic low grade inflammation in pathogenesis of PCOS. Int J Mol Sci 2021; 22(7): 3789.
[http://dx.doi.org/10.3390/ijms22073789] [PMID: 33917519]
[20]
Yoshimura M, Conway-Campbell B, Ueta Y. Arginine vasopressin: Direct and indirect action on metabolism. Peptides 2021; 142: 170555.
[http://dx.doi.org/10.1016/j.peptides.2021.170555] [PMID: 33905792]
[21]
Yeon Lee J, Baw CK, Gupta S, et al. Role of oxidative stress in polycystic ovary syndrome. Curr Womens Health Rev 2010; 6(2): 96-107.
[http://dx.doi.org/10.2174/157340410791321336]
[22]
Widecka J, Ozegowska K, Banaszewska B, et al. Is copeptin a new potential biomarker of insulin resistance in polycystic ovary syndrome? Ginekol Pol 2019; 90(3): 115-21.
[http://dx.doi.org/10.5603/GP.2019.0021] [PMID: 30949999]
[23]
Karbek B, Ozbek M, Karakose M, et al. Copeptin, a surrogate marker for arginine vasopressin, is associated with cardiovascular risk in patients with polycystic ovary syndrome. J Ovarian Res 2014; 7: 31.
[http://dx.doi.org/10.1186/1757-2215-7-31] [PMID: 24628831]
[24]
Enhörning S, Wang TJ, Nilsson PM, et al. Plasma copeptin and the risk of diabetes mellitus. Circulation 2010; 121(19): 2102-8.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.109.909663] [PMID: 20439785]
[25]
Canivell S, Mohaupt M, Ackermann D, et al. Copeptin and insulin resistance: Effect modification by age and 11 β-HSD2 activity in a population-based study. J Endocrinol Invest 2018; 41(7): 799-808.
[http://dx.doi.org/10.1007/s40618-017-0807-7] [PMID: 29235050]
[26]
Abbasi A, Corpeleijn E, Meijer E, et al. Sex differences in the association between plasma copeptin and incident type 2 diabetes: The Prevention of Renal and Vascular Endstage Disease (PREVEND) study. Diabetologia 2012; 55(7): 1963-70.
[http://dx.doi.org/10.1007/s00125-012-2545-x] [PMID: 22526609]
[27]
Nori W, Ali A I. Maternal alpha-1-antitrypsin as a noval marker for growth restriction in pre-eclampsia. J Obstet Gynaecol Res 2021; 47(2): 4250-55.
[http://dx.doi.org/10.1111/jog.15043]
[28]
Yoshida K, Kusama K, Fukushima Y, Ohmaru-Nakanishi T, Kato K, Tamura K. Alpha-1 antitrypsin-induced endoplasmic reticulum stress promotes invasion by extravillous trophoblasts. Int J Mol Sci 2021; 22(7): 3683.
[http://dx.doi.org/10.3390/ijms22073683] [PMID: 33916165]